文献速递乳腺癌放疗

每日一次大分割联合深吸气屏气三维适形部分乳腺放疗的初步毒性结果

Preliminary toxicity results using partial breast 3D-CRT with once daily hypo-fractionation and deep inspiratory breath hold.
PubMed 文献 · Radiat Oncol · 2018-07-27

本研究评估了37例早期乳腺癌患者术后接受三维适形大分割、深吸气屏气(DIBH)部分乳腺放疗(HIP)的临床结局。中位剂量42.56 Gy/16次,急性≤2级毒性79%,晚期1-2级毒性42%,无≥3级毒性,中位随访21个月无局部、区域或远处失败。

要点

  • HIP方案将每日一次乳腺大分割与部分乳腺治疗结合,中位剂量42.56 Gy/16次。
  • 急性≤2级毒性79%,最常见为皮炎(63%);晚期1-2级毒性42%,最常见为色素沉着(n=9)。
  • 无≥3级急性和晚期毒性,中位随访21个月无局部、区域或远处失败。

核心结论

  • 在该低风险早期乳腺癌队列中,HIP方案(三维适形外照射、中度大分割与DIBH的结合)报告的毒性有限。

研究设计与样本

  • 回顾性识别2013年至2014年在本机构接受肿块切除术后HIP治疗的37例患者共38个乳腺癌病灶。
  • 患者接受每日一次大分割(≤20次)部分乳腺放疗(肿块切除腔+边缘),无论侧别均使用DIBH。
  • 收集临床和治疗相关特征,包括靶区体积和危及器官(OAR)剂量学特征;临床随访并至少每年乳腺X线摄影,随访至36个月(范围5-36个月)。
  • 急性和晚期毒性采用不良事件通用术语标准(CTCAE)v4.03评分。

主要发现

  • 患者接受中位剂量42.56 Gy/16次(范围40.05-53.2 Gy;15-20次)。
  • OAR剂量较低,平均心脏剂量0.37 Gy,同侧肺V20平均4%,对侧肺V5为1%。
  • 急性毒性(≤2级)见于79%(n=30)的病例,最常见为皮炎(63%)。
  • 晚期1-2级毒性见于42%(n=16)的病例,最常见为色素沉着(n=9)。
  • 无严重急性或晚期毒性(≥3级);中位随访21个月,无局部、区域或远处失败。

关键数值与推荐

  • 患者接受中位剂量42.56 Gy/16次(范围40.05-53.2 Gy;15-20次)。
  • 平均心脏剂量0.37 Gy,同侧肺V20平均4%,对侧肺V5为1%。
  • 急性毒性(≤2级)79%(n=30),皮炎最常见(63%)。
  • 晚期1-2级毒性42%(n=16),色素沉着最常见(n=9)。
  • 无≥3级急性或晚期毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the clinical outcomes of patients treated with 3D conformal Hypo-fractionated, deep Inspiratory breath-hold (DIBH), Partial breast radiotherapy, termed "HIP." HIP was implemented to merge the schedule of once-daily breast hypofractionation with partial breast treatment. METHODS: We identified 38 breast cancers in 37 patients from 2013 to 2014 treated at our institution with HIP following lumpectomy for early stage breast cancer. Patients received a hypo-fractionated course (≤ 20 fractions) of once daily radiation to the partial breast (lumpectomy cavity + margin) utilizing DIBH regardless of laterality. Clinical and treatment-related characteristics were obtained, including target volume and organ at risk (OAR) dosimetric characteristics. Patients were followed clinically and with at least yearly mammograms for up to 36 months (range 5-36 months). Acute and late toxicity was scored using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. RESULTS: Patients received a median dose of 42.56 Gy in 16 Fractions (Fx) (range 40.05-53.2 Gy; and 15-20 Fx). OAR doses were low, with a mean heart dose of 0.37 Gy, an ipsilateral lung V20 mean of 4%, and a contralateral lung V5 of 1%. Acute toxicity (≤ grade 2) was present in 79% (n = 30) of the cases, with dermatitis being the most common finding (63%). Late grade 1-2 toxicity was present in 42% (n = 16) of the cases, with hyperpigmentation being the most common finding (n = 9). There were no severe acute or late toxicities (≥ grade 3). At a median follow up of 21 months, there were no local, regional, or distant failures. CONCLUSIONS: We report limited toxicity in this low risk cohort of patients with early stage breast cancer treated with HIP, a unique and logical combination of 3-D conformal external beam radiotherapy, moderate hypo-fractionation, and DIBH.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kowalchuk RO, Romano KD, Trifiletti DM, et al. Preliminary toxicity results using partial breast 3D-CRT with once daily hypo-fractionation and deep inspiratory breath hold. Radiat Oncol. 2018. PMID: 30053864. doi:10.1186/s13014-018-1079-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。